Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA approves Laser system for myopia

April 5, 1996

Chiron, Japan Tobacco alliance for combinatorial chemistry

April 5, 1996

Synthelabo reports antidepressants

April 5, 1996

5-HT1A/5-HT2C receptor ligands from Roche

April 5, 1996

New anthranilide in phase I at Glaxo Wellcome

April 5, 1996

L-745870: D4 antagonist for schizophrenia

April 5, 1996

New antipsychotic drug in phase I at P&U

April 5, 1996

New antipsychotic drugs from HMR

April 5, 1996

Meiji claims improved antipsychotic agents

April 5, 1996

Pherin develops vomeropherins for anxiety

April 5, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...